P1, N=20, Enrolling by invitation, Hospital for Special Surgery, New York | Active, not recruiting --> Enrolling by invitation | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
3 days ago
Enrollment open • Trial completion date • Trial primary completion date
AB-205 appears to be safe and potentially effective in subjects undergoing HDT-AHCT for lymphoma. Compared to published rates of 24-41% for G ≥3 OM (Singer 2019; Colita 2109) and 86% for FN (Caimi 2105) in subjects with systemic lymphoma, we observed 0% SRRT and 31% FN with the highest dose of AB-205 tested. AB-205 has significant potential to address a serious unmet medical need in patients undergoing HDT-AHCT and will be assessed in a forthcoming pivotal, double-blinded, placebo-controlled, randomized clinical trial for potential registration.